On December 24, 2020, the Federal Court issued a decision in a patent infringement action pursuant to s. 6(1) of the Patented Medicines (Notice of Compliance) Regulations relating to silodosin (Allergan’s RAPAFLO): Allergan Inc v Sandoz Canada Inc, 2020 FC 1189. Chief Justice Crampton found that Canadian Patent No. 2,507,002, relating to a capsule formulation of silodosin, is not invalid on the basis of obviousness but not infringed as “the Sandoz Product does not contain ‘granules’ and does not involve ‘granulating’ or a ‘wet granulation process’”, all of which were found to be essential elements.
The Court declined to consider the prosecution file history in determining whether certain claim elements were essential on the basis that s. 53.1 of the Patent Act permits admission of the prosecution history to rebut representations made by the patentee (Kissei in this case) in an action or application, not a licensee (Allergan in this case). The patentee made no representations to the Court regarding construction.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Janssen’s abiraterone acetate and prednisone combination therapy patent found invalid
On January 14, 2020, the Federal Court released a decision by Phelan J. in patent infringement actions pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (PMNOC R...Read More -
Federal Court holds section 8.2 of the PMNOC Regulations does not impose a limitation period
On December 22, 2020, the Federal Court issued its decision holding that section 8.2 of the PMNOC Regulations does not impose a limitation period either the same as or comparable to the 45-day limitat...Read More -
Federal Court reinstates decision that REMICADE new use patent is valid and infringed
As reported previously here, the Federal Court had found that Kennedy’s patent for infliximab (Janssen’s REMICADE) was valid and infringed by Hospira’s biosimilar INFLECTRA (“Trial Decision”).Read More